Роль инсулинорезистентности в развитии макрососудистых осложнений сахарного диабета 2 типа и пути ее коррекции
Диссертация
Большинство больных с сахарным диабетом 2 типа и висцеральным ожирением (87,8%) характеризуются наличием инсулинорезистентности, выраженность которой находится в прямой зависимости от длительности СД 2 типа, длительности и степени АГ, а также от тяжести нарушений углеводного и липидного обмена у данной группы пациентов. Инсулинорезистентность играет ведущую роль в развитии метаболических… Читать ещё >
Содержание
- ВВЕДЕНИЕ
- ГЛАВА 1. Современные представления о феномене инсулинорезистентности (ИР), его роли в развитии макрососудистых осложнений сахарного диабета 2 типа (СД 2 типа) обзор литературы)
- 1. 1. Роль ИР в развитии СД 2 типа и его макрососудистых ожнений
- 1. ^.Ррраненнь макрсудых ожнений СД 2 типа, оценкаммарногордечносудого ра
- 1. 1. 2. Роль ИР в развитии макрососудистых осложнений СД типа
- 1. 1. 3. Механизмы ИР и ее роль в развитии метаболичих нарушений при СД 2 типа
- 1. 1. 4. Веральное ожирение как маркер ИР, его роль в развитии СД 2 типа и макрсудитых ожнений
- 1. 2. Особенности терапии сахарного диабета 2 типа у пациентов с преобладанием ИР и повышенным риском макрососудистых ожнений
- 2. 1. Общая характерика клиничих наблюдений
- 2. 2. Методы оедования больных
- 2. 2. 1. Определение показателей углеводного и липидного обмена
- 2. 2. 2. Определение мы и рределения жировой ткани. Оценкакреторной активни жировой ткани
- 2. 2. 3. Определение илинорезентни
- 2. 2. 4. Методики проведения ЭХОКГ и СМАД
- 3. 1. Влияние ИР на развитие метаболических и гемодинамических нарушений у пациентов с СД 2 типа и оценка сердечно-сосудистого ра
- 3. 1. 2. Оценкаммарногордечносудого ра у пациентовСД 2 типа и ИР
- 3. 1. 3. Взаимязь ИР, верального ожирения и метаболичих нарушений у пациентовСД 2 типа
- 3. 2. Коррекция ИР у пациентовСД 2 типа комбинированной терапией метформином и рглитазоном (Авандия) и ее влияние на динамику метаболичих, гемодинамичих нарушений ирдечнсудый р
- 3. 2. 1. Влияние комбинированной терапии метформином и рглитазоном (Авандия) на гемодинамичие показатели ирдечносудый р
- 3. 2. 2. Метаболичие эффекты комбинированной терапии метформином и рглитазоном (Авандия)
- 3. 2. 3. Влияние комбинированной терапии метформином и росиглитазоном (Авандия) на висцеральное жировое депо и секреторную активнь жировой ткани
Список литературы
- Аметов А.С. Инсулиносекреция и инсулинорезистентность: две стороны одной медали.// Проблемы эндокринологии.- 2002.- Т.48, № 3.- С. 31−36.
- Аметов А.С. Сахарный диабет 2 типа. Основы патогенеза и терапии. Учебное пособие. // М, Медицина.- 2003.- С.7−62.
- Анциферов М. Б. Дорофеева Л.Г. Авандия (росиглитазон) современный инсулиновый сенситайзер для коррекции инсулинорезистентности при сахарном диабете типа 2.// Фарматека.-2005.- № 12.- С. 16−23.
- Аракелянц А. А. Горохова С.Г. Поражение сердца при сахарном диабете. // Российский кардиологический журнал.- 2004.-№ 1.-С.80−86.
- Балаболкин М.И., Дедов И. И. Гончаров Н.П. Динамика ключевых медиаторов инсулинорезистентности у больных сахарным диабетом 2 типа при применении метформина (Формин плива). // Сахарньщ диабет.- 2004.-№ 4.-С.42−54.
- Балаболкин М.И., Клебанова Е. М. Инсулинорезистентность в патогенезе СД 2 типа.// Сахарный диабет.- 2001.-№ 1 .-С.28−36.
- Балаболкин М.И., Клебанова Е. М., Креминская М. И. Бигуаниды: антигипергликемическое и вазопротективное действия. //Consilium Medicum.-2003.- Т.5 (9).-С. 487−491.
- Благосклонная М. В. Алмазов В.А. Красильникова Е. И. Общность патогенетических механизмов ИБС и инсулиннезависимого сахарного диабета, профилактика, лечение.// Кардиология.-1996.-№ 5.-С. 35−39.
- Благосклонная М. В. Шляхто Е.В. Красильникова Е. И. Туловищное ожирение и инсулинорезистентность ключевое звено метаболического сердечно-сосудистого синдрома. //Сахарный диабет.- 2003.-№ 1.-С.12−15.
- Боухеннон H.Д. Ишемическая болезнь сердца и диабет. Вторичная профилактика заслуживает большего внимания. //Международный медицинский журнал.-1999.-№ 2.-С. 396−402.
- Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению.// Русский медицинский журнал.- 2001.-№ 2.-С. 56−60.
- Бутрова С.А., Дзгоева Ф. Х. Висцеральное ожирение ключевое звено метаболического синдрома.// Ожирение и метаболизм.- 2004.-№ 1.-С. 10−16.
- Дедов И. И. Александров A.A. Диабетическое сердце: Causa magna. // Сердце.-2004 .- ТЗ № 1(13).- С. 5−8.
- Дедов И.И., Мельниченко Г. А. Ожирение: этиология, патогенез, клинические аспекты.// М, МИА.-2004.-С 44−84.
- Дедов И. И. Сунцов Ю.И. Кудрякова C.B. Экономические проблемы сахарного диабета в России. // Сахарный диабет.-2000.- № 3.- С.56−58.
- Дедов И. И. Шестакова М.В. Сахарный диабет.// М., Универсум Паблишинг.-2003 .- С. 231−242- 244−256- 263−267- 282−289.
- Дедов И. И. Шестакова М.В. Диабетическая нефропатия.// М., Универсум Паблишинг.- 2000 г.-С.239.
- Ивлева А.Я., Старостина Е. Г. Ожирение проблема медицинская, а не космическая. // М., Медицина.- 2002.-176с.
- Зимин Ю.В. Инсулинорезистентность, гиперинсулинемия и артериальная гипертензия.// Кардиология.- 1996.-№ 11.-С.80−91.
- Кабалава Ж.Д., Терещенко С. Н., Калинкин A.JI. Суточное мониторирование артериального давления: методические аспекты и клиническое значение.// Москва. 1997.- 32с.
- Клебанова Е.М., Креминская М.И, Балаболкин М. И. Росиглитазон и другие тиазолидиндионы в лечении сахарного диабета типа 2.// Фарматека.-2005.-№ 3.-С 14−18.
- Кононенко И. В. Смирнова О.М. Роль синтетичекого лиганда PPARy росиглитазона в патогенетическом лечении сахарного диабета 2 типа. // Сахарный диабет.- 2005.-№ 2.- С.66−73.
- Кононенко И.В. Смирнова О.М. PPARy-представитель семейства ядерных стероидных рецепторов.// Сахарный диабет.- 2005.-№ 2, — С.74−78.
- Мамедов М.Н., Перова Н. В., Метельская В. И. Компоненты метаболического синдрома у больных с артериальной гипертонией // Кардиология. 1997. — Т. 37, № 12. — С. 37−41.
- Мельниченко Г. А. Ожирение в практике эндокринолога. // РМЖ.-2001.-9 (2).-С. 82−87
- Мычка В. Б. Масенко В.П., Чазова И. Е. Артериальная гипертония на фоне избыточного веса: особенности терапевтического подхода. // Ожирение и метаболизм.- 2006. -№ 3(8). С. 46−51.
- Мычка В. Б. Чазова И.Е. Сердечно-сосудистые осложнения сахарного диабета типа 2. // Consilium Medicum.- 2003.- Т.5(9).- С. 504−509.
- Недосугова JI.B. Возможные механизмы антиатеросклеротического эффекта’глюкофажа(метформина). // Сахарный диабет.- 2006.- № 3.- С. 6−11.
- Ольбинская Л.И., Мартынов А. И., Хапаев Б. А. Мониторирование артериального давления в кардиологии.// Москва.- 1998.- 99 с.
- Палеев Н. Р. Калинин А.П. Мравян С. Р. Сахарный диабет и сердце. // Клиническая медицина.- 2005.- № 8.- С.37−42.
- Панов A.B. Лаевская М. Ю. Сахарный диабет типа 2 и атеросклероз: тактика гиполипидемической терапии.// Consilium Medicum. 2002. — T4(ll).-С 560−565.
- Перова Н.В., Мамедов М. Н., Метельская В. А. Кластер факторов риска сердечно-сосудистых заболеваний: метаболический синдром. // Международный Медицинский Журнал.- 1999. -№ 2.- С.21−24.
- Соколов Е.И. Сахарный диабет и атеросклероз. // М, Универсум паблишинг.- 1998.- с.38−47.
- Соколов Е.И. Диабетическое сердце.// Москва. 2002. — 416с.
- Старостина Е.Г. Бигуаниды: второе рождение. // Новый медицинский журнал.-1998.-№ 1 .-С. 3−8.
- Ушкалова Е.А. Метформин: ренессанс при сахарном диабете типа 2 и перспективы при других заболеваниях, сопровождающихся инсулинорезистентностью. // Фарматека, — 2005.- № 3.- С.33−46.
- Чазова Л. С. Калинина A.M., Маркова Е. В., Павлова Л. И. Сахарный диабет: распространенность, связь с факторами риска ИБС, прогностическое значение.// Терапевтический архив.- 1989 .- С. 15−18.
- Шубина А. Т. Демидова И.Ю. Карпов Ю. А. Метаболический синдром X: предпосылки развитию артериальной гипертензии и атеросклероза.// Клиническая фармакология и терапия.- 2001.- № 10(4).- С.44−47.
- Шестакова М.В. Блокада ренин-ангиотензиновой системы в профилактике сахарного диабета типа 2.// Consilium Medicum. 2005.- Т 7,№ 9.- С.743−746.
- Шестакова М.В., Брескина О. Ю. Инсулинорезистентность: патофизиология, клинические проявления, подходы к лечению. // Consilium-Medicum. 2002.- 4(10).- С. 11−17.
- ШиллерН., Осипов М. Клиническая эхокардиография.// Москва.- 1993.-С.68−82.
- Чазова Л. С. Калинина A.M., Маркова Е. В., Павлова Л. И. Сахарный диабет: распространенность, связь с факторами риска ИБС, прогностическое значение.//Терапевтический архив.- 1989.-С. 15−18.
- Abbasi F., Chu J.W., Lamendola C., McLaughlin T., Reaven GM Discrimination between obesity and insulin resistance in the relationship with adiponectin.// American Diabetes Association, Inc., Diabetes.- 2004. 53(4). — P. 939−947.
- Alzaid A. Insulin resistance in non-insulin-dependent diabetes mllitus.//Acta Diabetol. 1996. Vol.33. — P. 87−99.
- Anderson PJ, Critchley JA, Chan JC, Cockram CS, Lee ZS. Factor analysis of the metabolic syndrome: obesity vs. insulin resistance as the central abnormality. // Int J Obes Relat Metab Disord. 2001.-7 (12). — P. 17 821 788.
- Anderson WD, Klein JL, Alexander RW et al. Early Atherosclerosis selectively impairs coronary artery endothelial function. // Circulation. 1992. -Vol.86 (suppl. 1).-P. 611−618.
- Assmann G., Cullen P., Schulte H. The Munster heart study (PROCAM). // Eur Heart J 1998- 19 (Suppl A). P. A2-A11.
- Bailey CJ Et al. Drug therapy: Metformin. The New England. // Journal of Medicine. 1996. — P. 334−574.
- Bailey CJ, Day C. Thiazolidinediones today. // Br. J of Diabetes Vase Dis. -2001.-Vol.1.-P. 7−13.
- Balkau B, Charles MA. Comments on the provisional report from the WHO consultation. // European Group for the Study of Insulin Resistance. Diabet Med. -1999.-№ 16.-P. 442−443.
- Banerji M. Lebovitz HE. et al. Rosiglitazone selectively increases subcutaneous, but not visceral adipose tissue mass in type 2 diabetes mellitus. -2001. № 50(Suppl.2). — P. A90.
- Beales P, Liddi R, Giorgini A. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. // Eur. J Pharmacol. 1998. — № 3 (57). -P. 221−225.
- Beales P, Liddi R, Giorgini A. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. // Eur. J Pharmacol. 1998. — 3(57) -P.221−225.
- Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR). // Drugs. 1999. — № 58. -P. 5−7.
- Bell D, Diabetic cardiomyopathy. // Diabetes Care. 2003. -№ 26. — P. 29 492 951.
- Berg AH, Combs TP, Du X, Brownlee M, Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. // Nat Med. 2001. -№ 7. -P. 947−953.
- Bergman R. Non-esterifed fatty acids and the liver: why is insulin secreted into the portal vein? // Diabetologia. 2000. — № 43. — P.946−953.
- Bierman EL, Lyman G. Duff Memorial Lecture: atherogenesis in diabetes. // Aterosclerosis and Thromb. 1992. -№ 12(6). — P. 647−656.
- Bjorntrop P. Abdominal obesity and risk. // Clin and Exper Hyper. Theory and Practice. — 1990. — A12 (5). — P.783−794.
- Bjorntrop P. The associations between obesity, adipose tissue distribution and disease.// ActaMed Scand.- 1987.- 723.- P.121−134.
- Bjomtorp P. Portal adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. //Aterosclerosis. 1990. -№ 10. — P. 493−496.
- Bjorntorp P. Metabolic difference between visceral and subcutaneous abdominal fat. // Diabetes Metab. 2000. — 26 (3). — P. 10−12.
- Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weickert MO, Mohlig M, Pfeiffer AF, Spranger J. Changes of adiponectin oligomer composition by moderate weight reduction. // Diabetes. 2005. — № 54. — P.2712−2719.
- Boden G. Shulman Gl. Free acids in obesity and type 2 diabetes: defining their rile in the development of insulin resistence and (3-cell dysfunction. // Eur J Clin Invest. 2002. — № 32 (suppl.3). — P. 14−23.
- Bray GA. Contemporary diagnosis and management of obesity. // Newtown, Pennsylvania, USA. 1998. — 289 p.
- Carey DG, Co win GJ, Galloway G. Sensitivity effect of rosiglinazone on insulin and body fat composition in type diabetic patients. // Obes. Res.- 2002. -№ 10. P.1008−1015.
- Carpenter J-L. Insulin-Induced and constitutive internalization of the insulin receptor. // Hormone Research. 1992. -№ 38. — P.13−18.
- Charlies MA, Morange P, Eschwege E. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese non-diabetic subjects: the BIGPROl Study.// Diabetes Care. 1998.- № 21P. 1697−1672.
- Clauser E, Leconte I, Auzan C., Molecular basis of Insulin Resistence. // Hormone Research.- 1992.- № 38.- P. 5−12
- Colditz GA, Willett WC, Rotnitzky A, Manson B. Weight gain as a risk factor for clinical diabetes mellitus in women. // Ann Intern Med. 1995. — № 122. — P. 481−486.
- Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.// Eur Heart J 2003.-№ 24.- P.987−1003.
- Coronary Heart Diseases: Reducing the Risk. International Task Force 11 Nutrition, metabolism and cardiovascular diseases. 1998. — Vol. 8, № 4.
- Couter C, Delarue J, Constans T. Age-related Insulin Resistance: a review.// Hormone Research.- 1992.-№ 38.-P.46−50
- DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus: a blanked overview. // Diabetologia. 1992. — Vol.35. — P. 389−397
- DeFronzo R.A. The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. // Diabetes. 1988. — 37. — P. 667−687.
- DeFronzo R.A., Goodman A, Multicenter Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. // N Engl J Med.- 1995. -№ 333.-P. 541.
- DeFronzo RA, Tobin JD, Andres R: The glucose clamp technique: A method for quantifying insulin secretion and resistance. // Am J Physiol. 1979. -Vol. 6.-P. 214−230.
- DeFronzo R. A, Ferranini E., Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. // Diabetes Care. 1991. — № 14. — P. 173−194.
- Deveraux R., Alonso D., Lulas E. et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. // Am. J. Cardiol. -1986. Vol. 57. — P. 450−458.
- Diamant M, Heine RJ. Thiazolidindionediones in type2 diabetes mellitus: current clinical evidence. // Drugs. 2003. — № 63. — P. 1373−1405.
- Dyslipidemia Management in Adults with Diabetes. //Diabetes Care. 2004. -№ 27. — P. S68−71.
- Ernst E., Reach K.L. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. // Ann Intern Med. 1993. — № 118. — P. 956 963.
- Ferranini E. Insulin resistance versus insulin deficiency in non-insulin dependent diabetes mellitus: problems and prospects. // Endocrine Rev. 1998. -№ 19. — P. 477−490.
- Ferranini E., Buzzigoli G., et al. Insulin resistance in essential hypertension. // N Engl J Med. 1987. — № 317. — P. 370−377.
- Ferranini E., De Frozo R.A. The association of hypertension, diabetes and obesity: a review. // J Nephrol. 1989. -№ 1. -P.3−15.
- Folli F., Saad MJA, Velloso L. et al. Crosstalk between insulin and angiotensin II signaling systems. // Exp Clin Endocrinol Diabetes. 1999. -№ 107. -P.133−139.
- Fonseca VA., Biswas N., Salzman A. Once-daily rosiglitazone in combination with metformin effectively reduced hyperglycemia in patients with type 2 diabetes. // Diabetes. 1999. — № 48. — P. A 100.
- Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris Prospective Study. //Diabetes Care. 1991. — № 14(6). -P. 461−469.
- Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. // Ann Intern Med. 2000. — № 132. — P. l 18−121.
- Fox KR, Peters DM, Arpe P, Bell M. Assessment of abdominal fat development in young adolescents using magnetic resonance imaging.// Int J Obesity. -2000. № 24. — P. 1653−1659
- Fraser R., Davies D.L. Connell M.C. Hormones and hypertension. // Clin. Endocrinol. 1989. — Vol. 31(№ 66) — P. 701−746.
- Friedwald WT., Levy RL, Fredrickson DS. Estimation of the concentratic of low-density lipoprotein cholesterol in plasma without use of preparath ultracentrifuge.// Clin. Chem. 1972. — Vol. 18. — P. 499−509.
- Fruhbeck G, Gomez-Ambrosi J, Mumzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation.// Am J Physiol Endocrinol Metab. 2001. — № 280. — P. 827- 847.
- Fruhbeck G., Salvador J. Relation between leptin and the regulates of glucose metabolism// Diabetologia. 2000. — № 43 (1).- P.3−12.
- Funahashi T. et al. Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia //The Journal of Clinical Endocrinology and Metabolism. 2001. — Vol.86. (№ 5).
- Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, Arita Y, Kihara S, Matsuzawa Y Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. // Intern Med. 1999. — № 38. — P.202−206.
- Gerich J. E. Is muscle the major site of insulin resistance in type 2 (non-insulin-dependent) diabetes mellitus? // Diabetologia. 1991. — № 34. — P.607−610.
- Godsland IF, Stevenson JC. Insulin resistance: syndrome or tendency? // Lancet. 1995. — № 346. — P. 100−103.
- Goldschmidt MG, Barret-Conner E, Edelstein SL. et al. Dyslipidaemia and ischaemic heart disease mortality among men and women with diabetes. // Circulation. 1994. — № 89. -P.991−997.
- Groop L. C, Salorauta C, Shank M et al. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and non-insulin dependent diabetes mellitus. // J Clin Endocrinol Metab. -1991. -№ 72. -P.96−107.
- Grossman W. Defining diastolic disfunction. // Circulation. 2000. -№ 101. -P.2020−2021.
- Grundy S.M. Vega G.L. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. // Arch Intern Med.-1992. -№ 152. -P.28−34.
- Guagnano MT, Ballone E, Colagrande V, Vecchia DR, Manigrasso MR, Merlitti D, Ricciono G, Sensi S. Large waist circumference and risk of hypertension. // Int J Obesity. 2001. -№ 25. — P. 1360−1364.
- Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glicaemic control and reduction of metabolic rise factors.//Eur J Clin Pharmacol. 1993. — № 44. — P. 107−112.
- Gulli G, E Ferrannini, M Stern, et al. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. // Diabetes. 1992. — Vol. 41. — P. 1575−1586.
- Haffner S. Insulin and Blood Pressure in the San Antonio Heart Study: A Review. // Circulation. 1993- № 1. -P. 18−27.
- Haffner SM The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. // Endocrine reviews. 1998. — Vol.19. -№ 5. — P.583−592.
- Haffner R., HustonH. Insulin resistance and dislipidemia. // Diabetologia. -1992(vol.5). P. 34−39.
- Haffner SM., Lehto S, Ronnemaa T., Mortality from coronary artery disease in subject with type 2 diabetes and nondiabetic subjects with and without myocardial infarction.// N Engl. J Med. 1998.- № 339.- P.229−234.
- Haschimi K.E., Lehnert H. Leptin Resistance or why leptin fails to work in obesity. // Exp Clin Endocrinol. — 2003. — № 111. — P. 2−7.
- Heart Outcomes Prevention Evaluation Studi Investigatores. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of HOPE study and MICRO-HOPE substudy. // Lancet. -2000. -№ 355. -P. 253−259.
- Henry R.M. et al. Left ventricular mass increases with deteriorating Glucose tolerance, especially in women: independence of increased arterial stiffness or decreased flow-mediated dilation // Diabetes care. 2004. — № 27. — P.522−529.
- Hilton PJ. Na+ transport in hypertension. // Diabetes Care. -1991. Vol.14. -P.233−239.
- Hotamisligil GS, Arner P, Caro JF et al. Increased adipose tissue expressonof tumor necrosis factor-alpha in human obesity and insulin resistance. // J Clin Invest. 1995. — № 95. — P. 2409−2415.
- Hotamisligil GS, Shargill NS, Speigelman B. M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. // Science. -1993.- № 259.-P. 87−91.
- Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. // Arterioscler Thromb Vase Biol. 2000. — № 20. — P. 1595−1599.
- Howard BV., Howard WJ. Dyslipidemia in non-insulin-dependent diabetes mellitus. // Endocrine reviews. 1994. — Vol. 15 (№ 3). — P. 263−274.
- Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. // J Biol Chem. 1996. — № 271. -P. 1697−1703.
- Inchiostro S., Bertoli G., Zanette G., Donadon V. Evidence of higher insulin resistance in NIDDM patients with ischemic heart disease. // Diabetologia. 1994. — № 37. — P. 597−603.
- Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. // Lancet. 1999. — № 353. — P.617−622.
- Janka H. Effects of hypertension on diabetic vascular complication. // Medicographia. 1991. — Vol. 13(5). — P.22−25.
- Jeng CY, Sheu WH, Fuh MM. Relationship between hepatic glucose production and fasting glucose concentration in patients with NIDDM. // Diabetes. -1994.-№ 43.-P. 1440−1444.
- Jones NP et al. Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin. // Diabetologia. 2000. — № 43. — P. A192.
- Joseph NA., Greenberg AS. Adipocytocines and insulin resistance. // J Clin Endocrinol. Metab. 2004. — № 89(2). — P. 447−460.
- Juhan-Vague I., Vague P., Alessi M Relationships between plasma insylin, triglyceride, body mass index and plasminogen activator inhibitor 1. // Diabetes Metab. 1987. — № 13. — P.331−336.
- Juhan-Vague I., Alessi M., Vague P., Increased plasma plasminogen activatoe ingibitor 1 levels. A possible link between insulin resistence and atherosclerosis. // Diabetologia. 1991. — № 34. — P. 457−462.
- Juhan-Vague I, Thompson SG. Involvement of the Hemostatic System in the Insulin Resistance Syndrome. A study of 1500 Patients with angina Pectoris. // Atherosclerosis and Trombosis. 1988. — Vol.13 (12). — P. 1865−1873.
- Juhan-Vague I., Vague P., Alessi M. Relationschips between plasma insulin, body mass index and plasminogen activator ingibitor 1. // Diabetes Metab. 1987. -№ 13.-P. 331−336.
- Kahn BB, Flier JS. Obesity and insulin resistance. // J Clin Invest. -2000. № 106 (4). — P.473−481.
- Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingam study. // Am Heart J. 1985. -№ 110(5). -P. 1100−1107.
- Kannel WB., McGree DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingam study. // Diabetes care. -1979. Vol.2. — P. 120−126.
- Kannel WB McGree DL. Diabetes and cardiovascular disease. The Framingam study. // JAMA. 1979. — Vol.241. — P. 2035−2038.
- Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. // Arch Intern Med. 1989. — № 149. -P.1514−1520
- Katz RJ, Ratner RE, Coher RM, et al. Are insulin and proinsulin independent risk markers for premature coronary artery disease? // Diabetes. 1996. -№ 45(6). -P. 736−741.
- Kasuga M. Insulin resistance and pancreatic (3 cell failure. // J Clin Invest. -2006. -№ 116(7). P. 1756−1760.
- Kelly DE, McKolanis TM. Comparative effects of rosiglitazone and metformine on fatty liver and visceral adiposity. // Diabetes. 2002. — № 51 (2). -P. A3 5.
- Keen H. WHO Multinational Study of Vascular Disease in Diabetes. (WHO MSVDD). //Diabetologia. -2001. -№ 44 (suppl.2). P. 87−88.
- Kern PA- Di Gregorio GB- Lu T- Rassouli N- Ranganathan G Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. // Diabetes. 2003. — № 52 (7). — P. 17 791 785.
- Khaw KT, Wareham N, Bingham S et al. Association of hemoglobin Ale with cardiovascular disease and mortality in adults: the European prospective investigationintro cancer in Norfolc. // Ann Intern Med.- 2004. -P.413−420.
- Kim YB, Ciardi TP., Kong A, Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3 -kinase activity and increases p 110b protein levels in skeletal muscule of type 2 diabetic subjects. // Diabetes. -2002. № 2. -P.51.
- Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. // Diabetes Care. 1995. — Vol.18. — P.258−268.
- Klip A, Leiter LA. Cellular mechanism of action of metformine. // Diabet Care. 1990. -№ 13. — P. 630−632.
- Kopelrnan PG. The effects of weight loss treatments on apper and lowbody fat. // Int. J. Obes. 1997. — № 21. — P.619−625.
- Kortelainen M.L. Association between cardiac pathology and fat tissue distribution in an autopsy series of men without premortem evidence of cardiovascular disease. // Int J Obesity. 1996. — № 20. — P. 245−252.
- Kostner GM. Karadi I. Lipiprotein alterations in diabetes mellitus. // Diabetologia. 1988. — Vol.31. — P.717−722.
- Krentz A.J. Insulin resistance. // Brit. Med. J. 1996. — Vol.31. — P. 1385−1389.
- Krolewski AS, Warram JH, Valsania P, et al. Evolving natural history of coronary artery disease in diabetes mellitus. //Am J Med. 1991. — 90(2A). — P. 56S-61S.
- Laakso M. et al. Insulin resistance in Finland.// Cardiovascular risk factors. -1993.-№ 3.-P. 44−53.
- Lansberg L. Insulin resistance, energy balance and sympathetic nervous system activity. // Clin Exp Hypertens. 1990. — A12. — P.817−830.
- Lansberg L. Pathophisiology of Obesity-related hypertension: role of insuline and sympathetic nervous system. // J of Cardiovasc. Pharmacology. 1994. -№ 23 (suppl.l). — P.1−8.
- Landsberg L. Obesity and the insulin resistance syndrome X. // Hypertens Res. 1996. -№ 19(1). -P.S51−55.
- Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. // Diabetologia. -2004. -№ 47. P. 240 248.
- Lebovitz HE, Dole IF, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. // J Clin Endocrinol. Metab. -2001- Vol .86. -P.280−288.
- Lebovitz HE, Kreider M, Freed MI Evaluatuon of liver function in type 2 diabetic patients during clinical trials. // Diabetes Care. 2002. -№ 25. — P.815−821.
- Lee W.L., Cheung A.M., Cape D., Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. // Diabetes Care. 2000. — № 23. — P. 962−968.
- Lee Y, Hirose H., Ohneda M et al. B-cells lipotixity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte (3-cell relationships. // Proc Natl Acad Scien. 1994. — № 91. — P. 1078−1088.
- Libby P. Ridker PM. Maseri A. Inflammation and atherosclerosis. // Circulation. 2002. -№ 105. — P. 1135−1143.
- Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. // Lancet. 2002. -№ 360. — P.57−58.
- Long-term results of Kumamoto study on optimal diabetes control in type 2 diabetic patients. // Diabetes Care. -№ 23 (suppl.2). B21-B29.
- Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. // Nat Med. 2002. — № 8. -P.731−737.
- Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. // Arch Intern Med. 1991.-№ 151.-P. 1141−1147.
- Matsuzawa Y, Maruoka S. Decreased plasma adiponectin concentrations in women with dyslipidemia. // J Clin Endocrin Metabol. 2002. -№ 87. — P.2764−2769.
- Matsuzawa Y, Shimomura I, Kihara S, Funahashi T. Importance of adipocytokines in obesity-related diseases. // Horm Res.- 2003. 60(Suppl 3). -P.56−59.
- McGarry JD. Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. //Diabetologia. 1999. -№ 42. — P.128−138.
- Miyazaki Y., Glass L., Triplitt C. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type 2 disbetic patients. // Diabetologia. 2001. -№ 44. -P2210−2219.
- Miyazaki Y. He H. Rosiglitazone improves downstream insulin receptor signaling in the type 2 diabetic patients. // Diabetes. 2003. — № 52 (8). — P. 19 431 950.
- Miyazaki Y. Matsuda M, Mahacali A. Mechanisms of glucose lowering effect by rosiglitazone in patients with type 2 diabetes.// Diabetes. 2001. -Vol.50 (suppl. 2).-A126.
- Modan M., Halkin H. Hyperinsulinemia or increased sympathetic drive as a link for obesity and hypertension. // Diabetes Care. 1991. -№ 14. — P.470−487.
- Modan M., Halkin H., Lusky A., Segal P., Fusch Z., Chetrit A. Hyperinsulinemia is characterized by jointly disturbed plasma VLDL, LDL, HDL levels. A population-based study. // Atherosclerosis. 1988. -№ 8. — P.227−236.
- Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. // Dialectologies. 2001. -№ 44. — S14−21.
- Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, events rates and case-fatality rates in 38 populations from 21 countries in four continents. // Circulation. 1994. -№ 90. — P. 583−612.
- Nagi DK, Yudkin JS. Effects of metformin on insuline resistance, risk factors for cardiovascular disease and plasminogen activator ingibitor in NIDDM subjects. A study of two ethnic groups. // Diabetes Care. 1993. -№ 16. — P.621−629
- Nathan D. M., Buse J. B., Davidson M. B., Heine R.J., Holman R. R., Zinman B. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. // Diabetes Care. 2006. -№ 49. — P. 1711−1721.
- Neaton JD, Wentworth DN, Cutler J, Stamler J, Kuller L. Risk factors for death from different types of stroke. Multiple Risk Factor Intervention trial Reasearch Group. //AnnEpidemiol. 1993. -№ 3. — P.493−499.
- Neel J, Julius S, Weder A. Et al. Syndrome X: it for real? // Genet Epidemiol. -1998. -№ 15.- P.19−32.
- Obesity: preventing and managing the global epidemic. Report of a WHO consultation on Obesity.// Geneva, World Health Organization. 1997. — 276 p.
- Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS. Adiponectin acts in the brain to decrease body weight. // Nat Med. -2004. № 10. — P.524−529.
- Ouchi N., Kihara S., Arita Y. et al. Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-kB signaling through camp-dependent pathway. // Circulation. 2000. — № 102. -P. 1296−1301.
- Pajavani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensivity. // Curr.Diab. Rep. 2003. -№ 3. — P.207−221.
- Park KS. Ciaraldi TP. Abrams-Carter L. et.al. Troglitazone regulation of glucose metabolism in human skeletal muscule cultures from obese type 2 diabetic subjects. // J Clin Endocrinol. Metab. -1998. -№ 83 -P. 1636−1643.
- Pereira RI, DrazninB. Inhibition of the phosphatidylinositol 3'-kinase signaling pathway leads to decreased insulin-stimulated adiponectin secretion from 3T3L1 adipocities. //Metabolism. -2005. -№ 54 (12). -P. 1636−1634.
- Perriello G, Misericordia P, Volpi E. Acute anthihyperglycemic mechanism of metformin in NIDDM. Evidence for suppression lipid oxidation and hepatic glucose production. // Diabetes. -1994. -№ 43. P.920−928.
- Plosker GL, Faulds D. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. // Drugs. 1999. -№ 57. — P. 409−438.
- Pontiroli A, Carpa F, Veglia F, Genetic contribution of polymorphism of the GLUT 1 and GLUT 4 genes to the susceptibility to the type 2 diabetes mellitus in different population. // Acta Diabetol. 1996. — Vol.33. — P. 193−197.
- Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societes on Coronary Prevention. // Eur Heart J. 1998. — № 19. — P. 1434−503.
- Purnell J, Brunzell J. The central role of dietary fat, not carbohydrate, in the insulin resistance syndrome. //Curr Opin Lipidol. 1997. -№ 8 (1). — P. 17−22
- Pyorala K Relationship of glucose tolerance arid plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. //Diabetes Care. 1996. -№ 19. — P.54−61.
- Randle PJ, Garland PB, Hales CN et al. The glucose-fatty acid cycle, its role in insulin sensitivity and metabolic disturbances of diabetes mellitus.// Lancet. 1963-№ 1. -P.785−789.
- Reaven G.M. Role on insulin resistance in human diseases. // Diabetes 1998. -37.-P. 1595−1606.
- Reaven G.M., Bernstein, R., Davis, B., and Olefsky, J.M. Nonketotic diabetes mellitus: insulin deficiency or insulin resistance?// Am. J. Med. 1976.- № 60.-P.80−88.
- Reaven G. M Hollenbeck C., Chen Y. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. // Diabetologia. 1989. -№ 32. — P.52−55.
- Reaven G. M. Effect of Metformin on various aspects of Glucose, Insulin and Lipid Metabolism in patients with NIDDM with varying degrees of Hyperglycemia // Diabetes Metabolism Reviews. 1995.
- Ren J, Dominguez LI, Sowers JR, et al. Metformin, but not gliburide prevents high glucose-induced abnormalities in relaxation and transcellular Ca 2+ transients in adult rat ventricular myocytes. // Diabetes. 1999. -№ 48. — P.2059−2065.
- Richard P., Donahue A, and Trevor J Hyperinsulinemia and insulin resistance: association with cardiovascular risk. // Cardiovascular factors. -1993. P. 12−18.
- Robinson AC, Burke J, Robinson S, Jhonson DG, The effects of metformin on glicemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. // Diabetes Care. -1998. № 21. — P.701−705.
- Rosen ED. Spiegelman BM. Molecular regulation of adipogenesis. // Ann. Rev. Dev. Biol. 2000. — Vol.16. — P. 145−171.
- Ross R, Am J, Freeman J, Hudson R, Janssen I. Abdominal adiposity and insulin resistance in obese men. // Am J Physiol Endocrinol Metab. 2002.-№ 282. -P. 657−663.
- Ross R, Rissanen J, Hudson R. Sensitivity associated with the identification of visceral adipose tissue levels using waist circumference in men and women: effects of weight loss. // Int J Obesity. 1996. -№ 20. — P. 533−538.
- Salzman A, Murphy KJ. Posiglitazone: cardiac safety with long-term treatment in patients with type 2 diabetes. // Diab. Res. Clin. Pract. 2000. — № 50 — P.96A.
- Scandinavian Simvastatin Suirvial Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. // Lancet. -1994.-№ 344.-P.1383−1389.
- Scherer P.E. et al. Adipose tissue: from lipid storage compartment to endocrine organe. // Diabetes. 2006. -№ 6. — P.300−315.
- Seidell JC. The worldwide epidemic of obesity. Progress in obesity research. Edited by B. Guy-Grand, G. Ailhaud. 8th International Congress on Obesity.// © John Libbev & Company Ltd. 1999.- P. 661−668.
- Setter SM, Thams J, et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. // Clin Ther. -2003. -№ 25(12). -P.2991−3026.
- Shiamabukuro M, Levi M, Unger RH. Fatty acid-induced B-cells apoptosis: a link between obesity and diabetes. // Proc Natl Acad Sci 1998. -№ 95. — P.2498−2502.
- Simenian J, Kelly D. Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistence in N1DDM. // J. Appl. Physiol. 1997. -Vol. 83.-P. 166−171.
- Sjostrom C. D, Lissner L, Sjostrom L. Relationship between weight change, body composition and incidence of cardiovascular risk factors Obesity// Diabetes. -1996. -№ 20. P 95.
- Solini A, DeFroso RA. Insuline resistanse, hypertension and cellular ion transport systems. // Acta Diabetol. 1992. — Vol.29. — P.196−200.
- Sowers JR At the cutting edge. Insulin resistence and hypertension. // Mol. Cell. Endocrin. -1990. Vol.74. — P.87−89.
- Sowers JR. Obesity and cardiovascular disease. // Clin Chem.- 1998. -№ 44. -P. 1821−1825.
- Sowers J., Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. // Hypertension. 1993. -Vol. 26. — P. 869 879.
- Spigelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. // Diabetes. -1998. -№ 47. P.507−514.
- Shulman GI Cellular mechanisms of insulin resistance. // J Clin Invest. 2000. — № 106. -P.171−176.
- Smith T. Crowth hormone induced insulin resistance: role of the insulin receptor, IRS 1, GLUT 1, GLUT 4. // Am. J Physiol. — 1997. — Vol.272. — P. 10 711 079.
- Stears AJ, Byrne CD. Adipocyte metabolism and the metabolic syndrome. // Diabetes, Obesity and Metabolism. 2001-№ 3. — P. 129−142
- Stehouwer CDA Lambert J Doncer AJM van Hinsberg VWM Endotelial dysfunction and pathogenesis of diabetic angiopathy. // Cardiovasc Res. 1997. -Vol.34. — P. 55−68.
- Steinberg H., Brechtel G., Johnson A., Baron AD. Blood flow independently modulates insulin mediated glucose uptake (IMGU) in skeletal muscle. // Diabetes- 1993. -Vol. 42 (Suppl. 1). P. 415.
- Stener G. Update on the syndrome of insulin resistence and lipoprotein metabolism. // Am. J. Cardiol. 1994. -№ 10. — 23B-26B.
- Stratton JM, Adler Al, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective, observational study. // BMJ. 2000. — № 321- P. 405−412.
- Stumvoll M., Nurhjhan N. Et al Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. //N. Engl. J. Med. 1995. — 333. — P. 550−554
- Sun XJ, Crimmins DL, Myers MG Jr, et al. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. // Mol Cell Biol. 1993. -Vol. 13. -P. 7418−7428.
- Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adult (Adult Treatment Panel III). // JAMA. 2001. -№ 285. -P.2486−2497.
- Supiano MA, Hogikian RV, Marrow LA. Hypertension and insulin resistance: role of sympathetic nervous system activity. // Am J. Physiol. 1992. -Vol.363. — E 935−942.
- Takanashi M. J, Ikeda EA. Involvement of adgesion molecules in guvane monocyte adhesion to and transmigration through endothelial cells in vitro. // Atherosclerosis. 1994. -№ 110. — P. 73−81.
- Taskinen MR. Trigliceride is a major atherogenic lipid in NIDDM. // Diabetes Metab. Rev. 1997-№ 13. — P.93−98
- Taylor SI, Moller DE. Mutations of the insulin receptor gene, In: Insulin resistance. // Ed. D.E. Moller, N.Y. Wiley. 1993. — P.83−123.
- The National High Blood Pressure Education Program Working Group: National high blood pressure education program working group report on hypertension in diabetes. // Hypertension. 1994. — № 23. — P. 145−158.
- The Prospective Cardiovascular Munster Study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. // Am J Cardiol. 1987. -№ 59. — 9G-17G.
- Tikellis C, Wookey P, Candido R. Improved islet morphology after blockade of the rennin-angiotensin system in the ZDF rat. // Diabetes. 2004. -№ 53. — P. 989−97.
- Trujillo ME, Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. // J Intern Med. -2005. -№ 257. -P.167−175.
- Turner R.C., Millns H., Neil H.A. et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23).//BMJ.- 1998.- № 316.- P.823−828.
- Uemura S. Matsushita H, Li W. Diabetes mellitus enhances vascular matrix metalloproteainase activity: role of oxidative stress. // Circulation Research. 2001. -№ 88. -P.1291−1298.
- Virtanen KA, Hallsten K, Parkkola R. Differetial effects of rosiglitazone and metformine on adipose tissue glucose uptake in type 2 diabetes. //Diabetes. -2003. -№ 52. P.283−290.
- Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. // J Clin Invest. 2003. -№ 112. — P. 1796−1808.
- Werner AL Travaglini MT A review of rosiglitazone in type 2 diabetes mellitus.// Pharmacotherapy.- 2001.- Vol. 21(9).- P. 1082−1099
- Widen E., Ekstrand A., SaJoranta C, et al. Insulin resistance in Type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridemia. // Diabetologia. 1992.-№ 35.-P.l 140−1145.
- Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. // J Am Soc Nephrol. 2004. -№ 15. -P.2792−800.
- Wu MS, Jhonson P, Sheu WH, et al. Effect of metformin on carbonhydrate and lipoprotein metabolism in NIDDM patients. // Diabetes Care. 1990. -№ 13.- P. 1−8.
- Yamauchi T, Hara K, Kubota N, Terauchi Y, Tobe K, Froguel P, Nagai R, Kadowaki T Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and antiatherogenic adipokine. // Curr Drug Targets Immune Endocr Metabol Disord .-2003.-№ 3.P.243−254.
- Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. // Nature. 2003. -№ 423. -P.762−769.
- Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. // Nat Med. 2001. -№ 7. -P.941−946.
- Yki-Jarvinen H. Role of insulin resistance in the pathogenesis of NIDDM. // Diabetologia.-1995.-№ 38. P.1378−1388.
- Zhang Y, Proenca R, Maffel M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. //Nature. -1994.-№ 372.-P.425−432,
- Zimmet P, McCarty D, De Courten M. The Global epidemiology of NIDDM and the metabolic syndrome. // J Diabet Complicat. 1997- № 11- P.60−68.